about
Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.Gender difference in the prognostic value of estimated glomerular filtration rate at admission in ST-segment elevation myocardial infarction: a prospective cohort study.Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: A pathology study.Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents.P2Y12 platelet inhibition in clinical practice.Prognostic relevance of PCI-related myocardial infarction.Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix.One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent.1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies.Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent.Percutaneous coronary intervention for acute coronary syndrome due to graft failure: use of bare-metal and drug-eluting stents and subsequent long-term clinical outcome.Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent.Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial iClinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis.Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion: from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry.Five-year follow-up of the endothelial progenitor cell capturing stent versus the paxlitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis.Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome.Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients.Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study.Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure.Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitusSHORT-TERM AND LONG-TERM PROGNOSTIC VALUE OF THE TIMI RISK SCORE AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST-ELEVATION MYOCARDIAL INFARCTIONSurvival of patients after ST-elevation myocardial infarction: external validation of a predictive biomarker modelFirst-in-man intracoronary use of the Trevo® Pro 4 mechanical thrombectomy device for the retrieval of large intracoronary thrombus in patients with acute coronary syndromesAmsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME orThree-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry
P50
Q33553503-7E7CD9E3-F743-41DB-B2CA-3A8C7EA3DC08Q35800571-889488D7-991E-479F-B7F3-933BBFC5320FQ35876107-3A7E0A34-BC46-42DC-AE86-3D61B07DDCD6Q37185489-5129B7FE-C8CD-401D-89F4-41588F631E76Q37919640-48BCB21C-F921-4E20-9051-AD7E43F6CD2DQ37969927-A338FCE9-E581-4F34-B995-F5647AF103E0Q38084414-030E05F3-FD9B-4A51-80E5-046BE99BDB15Q38183938-37DA9C2F-5140-4E78-AB1D-F698E8E452CCQ39243200-570768AE-97C5-47BA-8923-DCF9C0FAC191Q39746722-B9D0D9FC-9BE2-4C83-83DD-3E7B1A600651Q43734387-4DC1F78C-501D-4C97-A4FA-E1218051762EQ44052707-E8B4DD42-FC2E-4D37-9133-CF089778C06AQ44919531-97CA7CCB-C604-4909-8A88-0EEFEAF03A6DQ44941164-00DBED1F-38FA-48F8-9E4D-3E501FA74795Q47743769-31A8CA5F-46A1-4A16-B798-A3BB4BF75191Q47890604-323655DA-F220-4CB7-804A-7439F45D5AEAQ47926846-38890276-678E-4B07-9F83-5ED50B724DFBQ48134319-CA57F73D-E7A5-4F10-BAEA-FE27975B8BF5Q48290107-71818720-5540-40D0-968A-06CF16F07922Q50063858-75D5C4F4-6083-4EF3-9221-726E75993B6CQ51066254-62D997B9-FAA2-49CA-B4F0-305C1B973AF3Q54495034-5EE6F39A-BB56-4A44-9EFB-A07F904B9FAEQ58886131-9B46CD7C-9A04-4275-BBD5-4699A9C10CF9Q64355449-8888B184-3581-4B51-8E52-19F7CBB97CCAQ83849574-77BFB4BD-4CB7-46C9-AD47-3673467C9845Q86963638-BB2B1A45-2059-454B-A00C-8AB41BF8583EQ87122267-30638748-97DA-4A29-B6B0-E7B7BCCC0243Q90628730-78A76153-9BD0-4E0E-A18C-AF851EA1ACDF
P50
description
researcher ORCID ID = 0000-0002-5870-9923
@en
wetenschapper
@nl
name
Pier Woudstra
@ast
Pier Woudstra
@en
Pier Woudstra
@es
Pier Woudstra
@nl
type
label
Pier Woudstra
@ast
Pier Woudstra
@en
Pier Woudstra
@es
Pier Woudstra
@nl
prefLabel
Pier Woudstra
@ast
Pier Woudstra
@en
Pier Woudstra
@es
Pier Woudstra
@nl
P31
P496
0000-0002-5870-9923